scholarly journals The effects of acute 17β-estradiol treatment on gene expression in the young female mouse hippocampus

2009 ◽  
Vol 91 (3) ◽  
pp. 315-322 ◽  
Author(s):  
Angela S. Pechenino ◽  
Karyn M. Frick
2019 ◽  
Vol 317 (5) ◽  
pp. L702-L716 ◽  
Author(s):  
Nathalie Fuentes ◽  
Marvin Nicoleau ◽  
Noe Cabello ◽  
Deborah Montes ◽  
Naseem Zomorodi ◽  
...  

Inflammatory lung diseases affect men and women disproportionately, suggesting that fluctuations of circulating hormone levels mediate inflammatory responses. Studies have shown that ozone exposure contributes to lung injury and impairment of innate immunity with differential effects in men and women. Here, we hypothesized that 17β-estradiol enhances inflammation and airway hyperresponsiveness (AHR), triggered by ozone exposure, in the female lung. We performed gonadectomy and hormone treatment (17β-estradiol, 2 wk) in C57BL/6J female and male mice and exposed animals to 1 ppm of ozone or filtered air for 3 h. Twenty-four hours later, we tested lung function, inflammatory gene expression, and changes in bronchoalveolar lavage fluid (BALF). We found increased AHR and expression of inflammatory genes after ozone exposure. These changes were higher in females and were affected by gonadectomy and 17β-estradiol treatment in a sex-specific manner. Gonadectomized male mice displayed higher AHR and inflammatory gene expression than controls exposed to ozone; 17β-estradiol treatment did not affect this response. In females, ovariectomy reduced ozone-induced AHR, which was restored by 17β-estradiol treatment. Ozone exposure also increased BALF lipocalin-2, which was reduced in both male and female gonadectomized mice. Treatment with 17β-estradiol increased lipocalin-2 levels in females but lowered them in males. Gonadectomy also reduced ozone-induced expression of lung IL-6 and macrophage inflammatory protein-3 in females, which was restored by treatment with 17β-estradiol. Together, these results indicate that 17β-estradiol increases ozone-induced inflammation and AHR in females but not in males. Future studies examining diseases associated with air pollution exposure should consider the patient’s sex and hormonal status.


PLoS ONE ◽  
2014 ◽  
Vol 9 (11) ◽  
pp. e111975 ◽  
Author(s):  
Gwendolyn I. Humphreys ◽  
Yvonne S. Ziegler ◽  
Ann M. Nardulli

2015 ◽  
Vol 12 (4) ◽  
pp. 887-896 ◽  
Author(s):  
Yutaka Nakachi ◽  
Mioko Iseki ◽  
Tomotaka Yokoo ◽  
Yosuke Mizuno ◽  
Yasushi Okazaki

Endocrinology ◽  
2012 ◽  
Vol 153 (12) ◽  
pp. 5888-5895 ◽  
Author(s):  
Paola Catanuto ◽  
Alessia Fornoni ◽  
Simone Pereira-Simon ◽  
Fayi Wu ◽  
Kerry L. Burnstein ◽  
...  

Abstract We recently showed that 17β-estradiol (E2) treatment ameliorated type 2 diabetic glomerulosclerosis in mice in part by protecting podocyte structure and function. Progressive podocyte damage is characterized by foot process effacement, vacuolization, detachment of podocytes from the glomerular basement membrane, and apoptosis. In addition, podocytes are highly dependent on the preservation of their actin cytoskeleton to ensure proper function and survival. Because E2 administration prevented podocyte damage in our study on diabetic db/db mice and has been shown to regulate both actin cytoskeleton and apoptosis in other cell types and tissues, we investigated whether actin remodeling and apoptosis were prevented in podocytes isolated from E2-treated diabetic db/db mice. We performed G-actin/F-actin assays, Western analysis for Hsp25 expression, Ras-related C3 botulinum toxin substrate 1 (Rac1) activity, and apoptosis assays on previously characterized podocytes isolated from both in vivo-treated placebo and E2 female db/db mice. We found that in vivo E2 protects against a phenotype change in the cultured podocytes characterized by a percent increase of F-actin vs. G-actin, suppression of Hsp25 expression and transcriptional activation, increase of Rac1 activity, and decreased apoptotic intermediates. We conclude from these studies that E2 treatment protects against podocyte damage and may prevent/reduce diabetes-induced kidney disease.


PLoS ONE ◽  
2016 ◽  
Vol 11 (9) ◽  
pp. e0161430 ◽  
Author(s):  
Winfred Stacey ◽  
Shreyas Bhave ◽  
Rosalie M. Uht
Keyword(s):  

PLoS ONE ◽  
2011 ◽  
Vol 6 (12) ◽  
pp. e28402 ◽  
Author(s):  
Jata Shankar ◽  
Thomas D. Wu ◽  
Karl V. Clemons ◽  
Jomar P. Monteiro ◽  
Laurence F. Mirels ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document